MedTrace Logo

Romidepsin Plus 3BNC117 Phase 2a Study

NCT02850016 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2022-07-14

Study results available
· View outcomes & findings →

Summary

The aim of this protocol is to evaluate the effects of romidepsin plus 3BNC117 or romidepsin alone on delaying or preventing viral rebound in ART-treated HIV-1-infected individuals during an analytical interruption of ART.

Conditions

  • Human Immunodeficiency Virus (HIV)

Interventions

DRUG

3BNC117

Intravenous Infusion of 3BNC117

DRUG

Romidepsin

Intravenous Infusion of Romidepsin

Sponsors & Collaborators

  • University Hospital of Cologne

    collaborator OTHER

  • Aarhus University Hospital

    collaborator OTHER

  • Rockefeller University

    lead OTHER

Principal Investigators

  • Marina Caskey, MD · Rockefeller University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-06
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • United States
  • Denmark
  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02850016 on ClinicalTrials.gov